ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis

Bookmark and Share
Published: 25 Jun 2020
Views: 525
Prof Efstathios Kastritis - University of Athens, Athens, Greece

Prof Efstathios Kastritis speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He discusses the latest results from the phase III ANDROMEDA study, which is evaluating the combination of subcutaneous daratumuab, cyclophosphamide, bortezomib and dexamethasone (CyBorD) to treat patients with newly-diagnosed light-chain (AL) amyloidosis.

Prof Kastritis outlines the design, findings and main conclusions of this study. 

He reports that this combination significantly improved hematologic response rate, while maintaining an acceptable safety profile and should become the new standard of care for these patients.

Read more about the study here.